Jun 10 |
TransCode Therapeutics regains compliance with Nasdaq
|
Jun 10 |
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
|
May 29 |
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
|
May 13 |
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
|
May 13 |
TransCode Therapeutics Open Letter to Shareholders
|
Apr 15 |
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
|
Apr 3 |
TransCode Therapeutics reports FY results
|
Apr 3 |
TransCode Therapeutics Reports 2023 Results; Provides Business Update
|
Mar 28 |
TransCode Therapeutics appoints Vlock as chief medical officer
|
Mar 28 |
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
|